SIX Swiss Exchange · Healthcare
Invest in Bachem stock from India
Indian and foreign residents can buy Bachem (BANB) shares directly through Paasa.
By Paasa · Updated
Bachem at a glance
- Price
- CHF 81.95+CHF 0.65 (0.80%)
- Market cap
- CHF 6.14B
- Day range
- CHF 81.20 – CHF 83.15
- P/E
- 41.18
- Dividend yield
- 1.10%
- Volume
- 106.96K
- 1 month
- +6.50%
- 6 months
- +30.29%
- YTD
- +40.21%
- 1 year
- +41.17%
- 5 years
- -41.21%
Bachem statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 695.1M | CHF 605.3M | CHF 577.3M | CHF 531.7M | CHF 503.2M |
| Gross profit | CHF 199.7M | CHF 182.6M | CHF 177.0M | CHF 171.3M | CHF 166.7M |
| Operating income | CHF 150.3M | CHF 133.0M | CHF 129.4M | CHF 126.3M | CHF 128.0M |
| Net income | CHF 148.8M | CHF 120.2M | CHF 111.9M | CHF 100.7M | CHF 114.7M |
| Earnings per share | CHF 1.98 | CHF 1.60 | CHF 1.50 | CHF 1.37 | CHF 1.62 |
| EBITDA | CHF 189.9M | CHF 178.8M | CHF 163.3M | CHF 160.5M | CHF 156.5M |
| Total assets | CHF 2.1B | CHF 1.9B | CHF 1.7B | CHF 1.4B | CHF 1.3B |
| Total debt | CHF 57.4M | CHF 290.0K | CHF 401.0K | CHF 691.0K | CHF 20.9M |
| Cash and short-term investments | CHF 31.0M | CHF 95.2M | CHF 298.5M | CHF 268.4M | CHF 442.4M |
| Shareholders' equity | CHF 1.5B | CHF 1.4B | CHF 1.3B | CHF 1.2B | CHF 1.1B |
| Operating cash flow | CHF 271.4M | CHF 146.3M | CHF 249.9M | CHF 92.6M | CHF 97.2M |
| Free cash flow | −CHF 48.2M | −CHF 138.3M | −CHF 18.5M | −CHF 49.8M | −CHF 19.7M |
| Capital expenditure | −CHF 319.6M | −CHF 284.6M | −CHF 268.4M | −CHF 142.3M | −CHF 116.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Ems-Chemie | EMSN.SW | CHF 828.00 | CHF 19.37B |
| Dottikon ES | DESN.SW | CHF 259.50 | CHF 3.59B |
| Clariant | CLN.SW | CHF 10.81 | CHF 3.56B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Bachem from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search BANB and buy
Find Bachem by name or by its ticker, BANB, and place your order.
Why invest in Bachem from India
What Bachem does
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Bachem operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Bachem stock from India?
Yes. Indian residents and NRIs can buy Bachem (BANB) shares directly through Paasa. Bachem is listed on the SIX Swiss Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Bachem shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.